New Study Identifies the Ability of ResistAid™ to Enhance Immune Response at Lower Dosage

November 13,2013

Basel, Switzerland, 13. November 2013 – New research demonstrates the ability of ResistAid™, Lonza’s proprietary, arabinogalactan-based immune support ingredient, to increase the antibody response in healthy adults after exposure to the Tetanus vaccine. Conducted at a dosage of 1.5 g/day, the study finds the efficacy of ResistAid™ at a significantly lower dosage, as compared to the 4.5 g/day that was previously found to be effective. The findings were recently published in the October issue of Journal of the American College of Nutrition, and can be found here: http://www.tandfonline.com/doi/full/10.1080/07315724.2013.839907 .

“This study further validates the capability of ResistAid™ to influence an expected and beneficial response from the immune system, while simultaneously confirming its ability to do so at a low dosage,” said Michael DeGennaro, NAFTA  VP Sales Human Nutrition - Lonza Inc. “In combination with its positive effects on both the innate and adaptive arms of the immune system, ResistAid™ is highly formulation-friendly. It can be easily incorporated into dietary supplements and functional foods in standalone form, or combined with other products to increase functionality.”

Vaccines trigger in vivo immune responses, which are indicators of immune function. The vaccine model is widely used to evaluate the impact a nutrient has on normal immune function and provides high quality information on the protective effect a nutrient has on in vivo immune responsiveness.

“This randomized, double-blind, placebo controlled trial demonstrated the ability of ResistAid™ at a dose of 1.5 g/day to significantly increase the IgG antibody response to the Tetanus vaccine, as compared to a placebo,” said Bryan Rodriguez, Global Product Manager, Arabinogalactan at Lonza. “In conjunction with earlier studies, this validates the effect of ResistAid™ on the augmentation of the response to bacterial antigens in the form of a vaccine.”

Subjects included 75 healthy adults (18-61 years old) who were randomized to receive either 1.5 g/day or 4.5 g/day of ResistAid™ or placebo for 60 days. At day 30, subjects were administered both Tetanus and Influenza vaccines. Serum antigenic response (Tetanus IgG, Influenza A and B IgG and IgM) were measured at days 45 (15 days after vaccination) and 60 (30 days after vaccination) of the study and compared to baseline antibody levels. As expected, all three groups demonstrated a rise in Tetanus IgG levels 15 and 30 days following the vaccine. There was a significant difference in the rise in Tetanus IgG levels at day 60 in the 1.5 g/day group compared to placebo (p = 0.008). Neither group demonstrated any significant elevations in IgM or IgG antibodies compared to placebo following the Influenza vaccine.  

ResistAid™ is a proprietary natural immune support ingredient made from larch trees. ResistAid™ consists of the soluble polysaccharide arabinogalactan and bioactive polyphenolic flavonoids, and thus has antioxidant capacity. ResistAid™ is formulated to deliver triple action immune benefits year round by supporting both the innate and adaptive immune responses as well as gastrointestinal health. Benefiting from a patented, water-based extraction process from U.S. larch trees, ResistAid™ is manufactured according to HACCP. It is GMP-audited by the American Institute of Baking, is Kosher certified by the United Mehadrin, GMO free and self-affirmed GRAS.

 

Browse All News
Bg